Related Experiment Video
Updated: May 2, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
Left ventricular systolic function following alcohol septal ablation for symptomatic hypertrophic cardiomyopathy
Travis J Moss1, Mori J Krantz2, Matthew M Zipse1
1Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Insights
Alcohol septal ablation (ASA) for hypertrophic cardiomyopathy (HC) preserves left ventricular (LV) systolic function in most patients. This treatment effectively reduces LV outflow tract obstruction and improves symptoms, with only mild LV dysfunction observed in a small minority.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Imaging
Background:
- Alcohol septal ablation (ASA) is a treatment for symptomatic hypertrophic cardiomyopathy (HC) with left ventricular (LV) outflow tract (LVOT) obstruction.
- ASA intentionally creates a myocardial infarct, raising concerns about potential long-term decline in LV systolic function.
Purpose of the Study:
- To evaluate the longitudinal changes in LV systolic function and other echocardiographic parameters in patients undergoing ASA for symptomatic HC.
Main Methods:
- A cohort of 145 consecutive patients with HC who underwent 167 ASA procedures between 2002 and 2011 were studied.
- Echocardiographic follow-up, including LV ejection fraction (LVEF), mitral regurgitation, and LVOT gradients, was performed on 139 patients (96%) over a mean of 3.1 years.
Main Results:
- LV ejection fraction (LVEF) was preserved in 97.1% of patients, with only 4 patients (2.9%) developing mild LV systolic dysfunction (LVEF 44-54%).
- Significant improvements were observed in mitral regurgitation severity (67% improved), resting LVOT gradient (75 to 19 mm Hg), provoked LVOT gradient (101 to 33 mm Hg), and New York Heart Association class (2.9 to 1.3).
Conclusions:
- Alcohol septal ablation for symptomatic HC results in only mild reduction of LV systolic function in a minority of patients.
- The procedure leads to significant improvements in echocardiographic and functional parameters, supporting its role in managing HC.
Abstract:
Because alcohol septal ablation (ASA) for the treatment of symptomatic hypertrophic cardiomyopathy (HC) with left ventricular (LV) outflow tract (LVOT) obstruction results in a myocardial infarct of up to 10% of ventricular mass, LV systolic function could decline over time. We evaluated LV function during longitudinal follow-up in a cohort of patients who underwent ASA. We studied 145 consecutive patients with HC that underwent 167 ASA procedures from 2002 to 2011. Echocardiographic follow-up was available in 139 patients (96%). Echocardiographic indexes included LV ejection fraction (LVEF), mitral regurgitation severity, systolic anterior motion of the anterior mitral leaflet, and resting and provoked LVOT gradients. All patients had a baseline LVEF of >55%. LVEF was preserved in 97.1% of patients over a mean follow-up time of 3.1±2.3 years (maximum 9.7). Mild LV systolic dysfunction was observed (LVEF range 44% to 54%) in only 4 patients. Mitral regurgitation severity improved in 67% (n=112 of 138 with complete data). Resting LVOT gradient declined from a mean of 75 to 19 mm Hg (p<0.001), and provoked gradient declined from a mean of 101 to 33 mm Hg (p<0.001). New York Heart Association class improved from a mean of 2.9±0.4 to 1.3±0.5 (p<0.001). In conclusion, LV systolic function is only mildly reduced in a minority of patients after ASA for symptomatic HC; other echocardiographic and functional measures were significantly improved.
More Related Videos
08:19Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
Published on: July 12, 2022
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology